Technology will allow Intradigm to use novel siRNA sequences into its RNAi delivery systems.



Intradigm has licensed intellectual property covering certain efficacy-enhancing structural elements of siRNA from the University of Massachusetts Medical School.


The licensed technology will allow Intradigm to incorporate novel siRNA sequences into its RNAi delivery systems. This IP includes parameters for the structural modifications for siRNAs including the Zamore Design Rules that improve the potency and efficacy of RNAi therapeutics, according to the company.








This site uses Akismet to reduce spam. Learn how your comment data is processed.